The Exact Science Behind Trying Not to Get Cancer

Today's ad-free episode of Out Of Patients is made possible by our friends at Exact Sciences, changing lives together through earlier detection and smarter answers. You know, I always love being the dumbest guy in the room because it bodes well that our discussions will be of the highest caliber of authenticity, trust, and the occasional 80s reference. I am grateful to welcome two genius humans who have uniquely accomplished insanely great things that have changed the world for the better. Dr. Paul Limburg is the Chief Medical Officer at Exact Sciences, and Dr. Nickolas Papadopoulos is a Professor of Oncology and Pathology at the Johns Hopkins University School of Medicine. Our conversation ranges from "meditainment" and a poor Sean Connery impression to a future where it may be possible for there to be something called MCED, or "Multi-Cancer Early Detection." We've been talking about cancer prevention for decades, but soon it may be possible to nip it in the bud before it gets awful—a future where one test can detect more than one type of cancer. That's progress. And, of course, it wouldn't be an episode with Exact Sciences without mentioning their groundbreaking diagnostic too, Cologuard. Strap in for a lesson on how the sausage is made (pun intended), along with a trip to the past, an examination of the present, and a look into the future. Enjoy the show.

To learn how to use Cologuard and for additional Important Risk information, visit www.cologuard.com. Samples for use with Cologuard must be collected with the Cologuard collection kit, including a stool sample for DNA testing and a stool sample for Hemoglobin testing, before returning the sample to EXAS laboratory for testing. MCED technology is under development and is not available commercially. It has not been cleared or approved by the US Food and Drug Administration (FDA).

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.